Literature DB >> 24375792

Peroxisome proliferator activated receptor-γ-Rho-kinase interactions contribute to vascular remodeling after chronic intrauterine pulmonary hypertension.

Jason Gien1, Nancy Tseng, Gregory Seedorf, Gates Roe, Steven H Abman.   

Abstract

Peroxisome proliferator-activated receptor-γ (PPARγ) and Rho-kinase (ROCK) regulate smooth muscle cell (SMC) proliferation and contribute to vascular remodeling in adult pulmonary hypertension. Whether these pathways interact to contribute to the development of vascular remodeling in persistent pulmonary hypertension of the newborn (PPHN) remains unknown. We hypothesized that ROCK-PPARγ interactions increase SMC proliferation resulting in vascular remodeling in experimental PPHN. Pulmonary artery SMCs (PASMCs) were harvested from fetal sheep after partial ligation of the ductus arteriosus in utero (PPHN) and controls. Cell counts were performed daily for 5 days with or without PPARγ agonists and ROCK inhibition. PPARγ and ROCK protein expression/activity were measured by Western blot in normal and PPHN PASMCs. We assessed PPARγ-ROCK interactions by studying the effect of ROCK activation on PPARγ activity and PPARγ inhibition (siRNA) on ROCK activity and PASMC proliferation. At baseline, PPHN PASMC cell number was increased by 38% above controls on day 5. ROCK protein expression/activity were increased by 25 and 34% and PPARγ protein/activity decreased by 40 and 50% in PPHN PASMC. ROCK inhibition and PPARγ activation restored PPHN PASMC growth to normal values. ROCK inhibition increased PPARγ activity by 50% in PPHN PASMC, restoring PPARγ activity to normal. In normal PASMCs, ROCK activation decreased PPARγ activity and PPARγ inhibition increased ROCK activity and cell proliferation, resulting in a PPHN hyperproliferative PASMC phenotype. PPARγ-ROCK interactions regulate SMC proliferation and contribute to increased PPHN PASMC proliferation and vascular remodeling in PPHN. Restoring normal PPARγ-ROCK signaling may prevent vascular remodeling and improve outcomes in PPHN.

Entities:  

Keywords:  Rho-kinase (ROCK); peroxisome proliferator-activated gamma (PPARγ); persistent pulmonary hypertension of the newborn (PPHN); pulmonary artery smooth muscle cells (PASMC); vascular remodeling

Mesh:

Substances:

Year:  2013        PMID: 24375792      PMCID: PMC3920199          DOI: 10.1152/ajplung.00271.2013

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  52 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  Attenuation of hypoxia-induced pulmonary artery remodeling by a peroxisome proliferator-activated receptor-gamma agonist.

Authors:  Joseph T Crossno; Kenneth G Morris; Dwight J Klemm
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

3.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

4.  Premature differentiation of vascular smooth muscle cells in human congenital diaphragmatic hernia.

Authors:  Ilona Sluiter; Irene van der Horst; Paul van der Voorn; Anne Boerema-de Munck; Marjon Buscop-van Kempen; Ronald de Krijger; Dick Tibboel; Irwin Reiss; Robbert J Rottier
Journal:  Exp Mol Pathol       Date:  2012-09-24       Impact factor: 3.362

Review 5.  Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes.

Authors:  W A Hsueh; S Jackson; R E Law
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

6.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

7.  A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.

Authors:  Kevin B Atkins; Brittany Irey; Nan Xiang; Frank C Brosius
Journal:  Am J Physiol Cell Physiol       Date:  2009-03-04       Impact factor: 4.249

8.  Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.

Authors:  Yahan Liu; Xiao Yu Tian; Guangmei Mao; Xi Fang; Man Lung Fung; John Y-J Shyy; Yu Huang; Nanping Wang
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

9.  Rho-kinase inhibitor prevents bleomycin-induced injury in neonatal rats independent of effects on lung inflammation.

Authors:  Alvin H Lee; Rupinder Dhaliwal; Crystal Kantores; Julijana Ivanovska; Kiran Gosal; Patrick J McNamara; Michelle Letarte; Robert P Jankov
Journal:  Am J Respir Cell Mol Biol       Date:  2014-01       Impact factor: 6.914

10.  Evolution of the nuclear receptor gene superfamily.

Authors:  V Laudet; C Hänni; J Coll; F Catzeflis; D Stéhelin
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  9 in total

Review 1.  Emerging concepts in smooth muscle contributions to airway structure and function: implications for health and disease.

Authors:  Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-10-14       Impact factor: 5.464

2.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

Review 3.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

4.  The Synergistic Enhancement of Cloning Efficiency in Individualized Human Pluripotent Stem Cells by Peroxisome Proliferative-activated Receptor-γ (PPARγ) Activation and Rho-associated Kinase (ROCK) Inhibition.

Authors:  Nasim-Sadat Kajabadi; Ali Ghoochani; Maryam Peymani; Kamran Ghaedi; Abbas Kiani-Esfahani; Motahareh-Sadat Hashemi; Mohammad Hossein Nasr-Esfahani; Hossein Baharvand
Journal:  J Biol Chem       Date:  2015-09-02       Impact factor: 5.157

Review 5.  Challenges, priorities and novel therapies for hypoxemic respiratory failure and pulmonary hypertension in the neonate.

Authors:  J L Aschner; J Gien; N Ambalavanan; J P Kinsella; G G Konduri; S Lakshminrusimha; O D Saugstad; R H Steinhorn
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

6.  Altered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia.

Authors:  Shannon N Acker; Gregory J Seedorf; Steven H Abman; Eva Nozik-Grayck; Katherine Kuhn; David A Partrick; Jason Gien
Journal:  Pediatr Res       Date:  2015-01-12       Impact factor: 3.756

7.  Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension.

Authors:  Valerie Nadeau; Francois Potus; Olivier Boucherat; Renee Paradis; Eve Tremblay; Marc Iglarz; Roxane Paulin; Sebastien Bonnet; Steeve Provencher
Journal:  Pulm Circ       Date:  2017-10-24       Impact factor: 3.017

8.  Monitoring Endothelin-A Receptor Expression during the Progression of Atherosclerosis.

Authors:  Miriam Stölting; Christiane Geyer; Anne Helfen; Anke Hahnenkamp; Marco V Usai; Eva Wardelmann; Michael T Kuhlmann; Moritz Wildgruber; Carsten Höltke
Journal:  Biomedicines       Date:  2020-11-26

9.  Association of DIAPH1 gene polymorphisms with ischemic stroke.

Authors:  Zhanyun Ren; Xiaotian Chen; Wuzhuang Tang; Jie Li; Song Yang; Yanchun Chen; Xianghai Zhao; Huihua Zong; Chunlan Liu; Chong Shen
Journal:  Aging (Albany NY)       Date:  2020-01-03       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.